CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: NDA 50761

CHEMISTRY REVIEW(S)

DIVISION OF ANTI-INFECTIVE DRUG PRODUCTS
Review of Chemistry, Manufacturing, and Controls

NDA #: 50-761 **CHEM.REVIEW #:** 2 **REVIEW DATE:** 2-APR-1999

SUBMISSION/TYPE	DOCUMENT DATE	CDER DATE	ASSIGNED DATE
ORIGINAL	15-APR-98	16-APR-98	15-MAY-98
AMENDMENT 1 (Stability)	08-SEP-98	11-SEP-98	11-SEP-98
AMENDMENT 2 (Stability)	13-JAN-99	16-JAN-99	16-JAN-99
AMENDMENT 3 (Stability)	24-FEB-99	1-MAR-99	1-MAR-99
AMENDMENT 4 (Response to Deficiencies)	23-MAR-99	24-MAR-99	26-MAR-99

NAME & ADDRESS OF APPLICANT:
SMITHKLINE BEECHAM PHARMACEUTICALS
One Franklin Plaza
P.O. Box 7929
Philadelphia, PA 19101-7929

DRUG PRODUCT NAME:

Proprietary:	Amoxil Chewable Tablets
Nonproprietary/USAN:	Amoxicillin Chewable Tablets
Code Names/#'s:	
Chemical Type/ Therapeutic Class:	3 S

ANDA Suitability Petition/DESI/Patent Status: N/A
[if applicable]

PHARMACOLOGICAL CATEGORY/INDICATION: Anti-infective

DOSAGE FORM: Chewable Tablets
STRENGTHS: 200 mg and 400 mg

ROUTE OF ADMINISTRATION: oral
DISPENSED: X Rx ___ OTC
CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOL.WT:

SmithKline Beecham

Amoxicillin Trihydrate $C_{15}H_{19}N_3O_5S.3H_2O$
(2S,5R,6R)-6-[(R)-(-)-2-amino-2-(p-hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0] heptane-2- carboxylic acid trihydrate.

CAS-61-336-70-7
M.W. 419.46



SUPPORTING DOCUMENTS:

Amoxicillin trihydrate drug substance

No DMF authorization is needed, the DMFs are held by the sponsor.
NDA 50-761 Review #1, 3/26/99.

RELATED DOCUMENTS (if applicable):
USP 23 Page 100
USP 23 Page 102
Other related Amoxil NDAs
NDA 50-726 - chewable tablet, 200mg and 400 mg
NDA 50-564 - tablet, 250mg and 500 mg
NDA 50-575 - Oral suspension, 125 mg/5 mL and 250 mg/5 mL
NDA 50-725 - Oral suspension, 200 mg/5 mL and 400 mg/5 mL

For HDPE bottles, No DMF authorization is needed, the DMFs are held by the sponsor.

Other DMFs:
DMF
DMF
DMF

DMF

DMF
DMF
DMF
DMF
DMF

The firm has provided DMF authorization letters.

CONSULTS:

A consult was sent to the Labeling and Nomenclature (L&C), and the nomenclature was found to be acceptable.

REMARKS/COMMENTS :

This review addressed the CMC deficiencies sent by facsimile transmission on March 4, 1999 to SB. All other items are adequate as discussed in Chemistry Review #1, dated 3/26/99.

CONCLUSIONS & RECOMMENDATIONS:

Recommend approval from the manufacturing and controls standpoint. All pending issues have been satisfactory resolved. All manufacturing facilities are currently in acceptable GMP compliance, except the site is pending Inspections).

/S/

Andrew Yu, Review Chemist

cc: Orig. NDA 50-761
HFD-520
HFD-520/DivDir/JSoreth
HFD-520/Chem/AYu
HFD-520/MO/MMakhene
HFD-520/MAlbuerne
HFD-520/Pharm/ROsterberg
HFD-520/Micro/SAltaire
HFD-520/CSO/JCintron
R/D Init by: HFD-520/TmLdrChem/ DKatague DBK 4/6/99

HFD-520/S. TROSTLE

MAR 12 1999

DIVISION OF ANTI-INFECTIVE DRUG PRODUCTS
Review of Chemistry, Manufacturing, and Controls

NDA #: 50-761 **CHEM.REVIEW #:** 1 **REVIEW DATE:** 10-MAR-1999

SUBMISSION/TYPE	DOCUMENT DATE	CDER DATE	ASSIGNED DATE
ORIGINAL	15-APR-98	16-APR-98	15-MAY-98
AMENDMENT 1 (Stability)	08-SEP-98	11-SEP-98	11-SEP-98
AMENDMENT 2 (Stability)	13-JAN-99	16-JAN-99	16-JAN-99
AMENDMENT 3 (Stability)	24-FEB-99	1-MAR-99	1-MAR-99

NAME & ADDRESS OF APPLICANT:
SMITHKLINE BEECHAM PHARMACEUTICALS
One Franklin Plaza
P.O. Box 7929
Philadelphia, PA 19101-7929

DRUG PRODUCT NAME:

Proprietary:	Amoxil Chewable Tablets
Nonproprietary/USAN:	Amoxicillin Chewable Tablets
Code Names/#'s:	
Chemical Type/ Therapeutic Class:	3 S

ANDA Suitability Petition/DESI/Patent Status: N/A
[if applicable]

PHARMACOLOGICAL CATEGORY/INDICATION: Anti-infective

DOSAGE FORM: Chewable Tablets
STRENGTHS: 200 mg and 400 mg

ROUTE OF ADMINISTRATION: oral
DISPENSED: X Rx ___ OTC
CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOL.WT:

Amoxicillin Trihydrate $C_{15}H_{19}N_3O_5S.3H_2O$
(2S,5R,6R)-6-[(R)-(-)-2-amino-2-(p-hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0] heptane-2-carboxylic acid trihydrate.
CAS-61-336-70-7
M.W. 419.46



SUPPORTING DOCUMENTS:

Amoxicillin trihydrate drug substance

No DMF authorization is needed, the DMFs are held by the sponsor.

RELATED DOCUMENTS (if applicable):
USP 23 Page 100
USP 23 Page 102
Other related Amoxil NDAs
NDA 50-726 - chewable tablet, 200mg and 400 mg
NDA 50-564 - tablet, 250mg and 500 mg
NDA 50-575 - Oral suspension, 125 mg/5 mL and 250 mg/5 mL
NDA 50-725 - Oral suspension, 200 mg/5 mL and 400 mg/5 mL

For HDPE bottles, No DMF authorization is needed, the DMFs are held by the sponsor.

Other DMFs:
DMF
DMF
DMF
DMF
DMF
DMF
DMF
DMF

The firm has provided DMF authorization letters.

CONSULTS:

A consult was sent to the Labeling and Nomenclature (L&C), and the nomenclature was found to be acceptable.

REMARKS/COMMENTS :

In addition to the 4 facilities listed, [redacted] was added through an amendment on 30-MAR-98. All five facilities were approved based on either profile or actual inspection.

CONCLUSIONS & RECOMMENDATIONS:

The application is **not** approvable for manufacturing and controls under section 505(b) of the Act. Specific items which are not approvable are identified under the following headings: Drug Products [Specification and Methods for Drug Product, and Labeling]. All manufacturing facilities are currently in acceptable GMP compliance or pending[redacted]

/S/

Andrew Yu, Review Chemist

cc: Orig. NDA 50-760
HFD-520
HFD-520/DivDir/GChikami
HFD-520/Chem/AYu
HFD-520/MO/MMakhene
HFD-520/MAlbuerne
HFD-520/Pharm/ROsterberg
HFD-520/Micro/SAltaire
HFD-520/CSO/STrostle
R/D Init by: HFD-520/TmLdrChem/ DKatague DBK 3/12/99